Цей переклад готується. Тимчасово ми показуємо оригінальну версію англійською мовою.
Бізнес · 11.06.19971 хв читання
Product, Establishment, and Biologics License Applications, Refusal to File; Meeting of Oversight Committee
Локальний автоматичний переклад · Оригінальна мова джерела
Короткий зміст
The Food and Drug Administration (FDA) is announcing the remaining 1997 meetings of its standing oversight committee in the Center for Biologics Evaluation and Research (CBER) that conducts a periodic review of CBER's use of its refusal to file (RTF) practices on product license applications (PLA's), establishment license applications (ELA's), and biologics license applications (BLA's). CBER's RTF oversight committee examines all RTF decisions which occurred during the previous quarter to assess consistency across CBER offices and divisions in RTF decisions.
Оригінальна мова джерела: Federal Register — Food and Drug AdministrationВідкрити оригінальне повідомлення →